Compare DexCom, Inc. (DXCM) vs Progressive Corp (PGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Progressive Corp — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Progressive Corp trades at $218.32 (market cap $126.95B). The key difference: Progressive Corp is far larger — about 4× DexCom, Inc.'s market cap, and Progressive Corp pays a 0.18% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Progressive Corp for 81 Days on average.
| DXCM | PGR | |
|---|---|---|
Market Cap | $31.86B | $126.95B |
Volume | 3,607,070 | 2,749,438 |
Sector | Health | Financials |
52-Week High | $92.34 | $242.16 |
52-Week Low | $54.84 | $190.40 |
Typical Hold Time | 62 Days | 81 Days |
Enterprise Value | $31.32B | $135.16B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Progressive Corporation (PGR) trades at $214.12, up 0.98% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with revenue growth from $49.6B in 2022 to $87.6B in 2025 and robust profitability metrics including 34.94% ROE. Recent earnings show mixed results with Q2 2026 beating expectations while Q1 2026 missed. Analyst consensus leans neutral with 52.38% hold ratings but a $222.23 price target suggests modest upside potential from current levels.
PGR presents a balanced investment case with solid fundamentals and reasonable valuation (P/E 10.97) offset by competitive pressures in personal auto insurance. The stock's technical strength and consistent revenue growth support potential upside, though investors should monitor underwriting discipline amid intensifying market competition. Key risks include execution challenges and macroeconomic sensitivity affecting insurance demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Progressive Corp
Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →
